A retrospective study of effect of SII on treatment outcomes in non-small cell lung cancer (NSCLC) patients treated with ICI
Latest Information Update: 08 Jul 2021
Price :
$35 *
At a glance
- Drugs Antineoplastics (Primary) ; Atezolizumab (Primary) ; Ipilimumab/nivolumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Carcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- 08 Jul 2021 New trial record
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology